Stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days and starting ...

The first clinical attempt to make human beings biologically younger is no longer a thought experiment. A small gene therapy ...

1) the active drug substance Axitinib, which used to belong to Pfizer, is an FDA-approved, oral, potent VEGFR inhibitor. So ...

Discusses 2026 Clinical Pipeline Outlook and Anticipated Trial Updates February 2, 2026 7:01 PM ESTCompany ParticipantsGary ...

Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular”), an integrated biopharmaceutical company committed to redefining the retina ...

Late-Breaking Science Abstract LB 032 - In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective medication, daily for 10 days starting ...

In a phase III clinical trial in China, stroke patients treated intravenously with loberamisal, a novel neuroprotective ...

Cereno Scientific is expanding development of CS014 to treat pulmonary hypertension linked to interstitial lung disease.

FDA priority review seeks marstacimab label expansion to ≥6 years with inhibitors and ages 6–11 without inhibitors, addressing populations with limited efficacy from factor replacement and high unmet ...

Diffuse Bio, a leading provider of AI and experimental platforms for designing and screening protein therapeutics, today announced significant enhancements to DiffuseSandbox, its self-serve protein ...

Biotechnology firm Ocugen has bolstered its financial position, securing a pathway through a pivotal period for its lead gene therapy candidate. The company's shares, currently trading at 1.26 euros, ...

Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.